Daily Courier: Single Column

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

150.03 +1.08 (+0.73%)
Streaming Delayed Price Updated: 4:00 PM EST, Mar 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,183,286
Open 147.87
Bid (Size) 148.50 (100)
Ask (Size) 150.03 (100)
Prev. Close 148.95
Today's Range 147.80 - 150.77
52wk Range 93.37 - 157.29
Shares Outstanding 1,253,809,440
Dividend Yield 2.11%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Compugen (CGEN) Q4 2025 Earnings Call Transcript ↗
Compugen (CGEN) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia
From Gilead Sciences, Inc.
Via Business Wire

Performance

YTD
+23.4%
+23.4%
1 Month
+5.0%
+5.0%
3 Month
+20.7%
+20.7%
6 Month
+33.1%
+33.1%
1 Year
+29.3%
+29.3%

More News

Read More
News headline image
Arcellx President Sells $10 Million Worth of Shares After Acquisition Announcement ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Arcellx President Sells $10M Worth of Shares After Acquisition Announcement ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
P/E Ratio Insights for Gilead Sciences ↗
Via Benzinga
What's going on in today's session: S&P500 movers ↗
Via Chartmill
Uncover the latest developments among S&P500 stocks in today's session. ↗
Via Chartmill
News headline image
Gilead Sciences Stock: Is GILD Outperforming the Healthcare Sector?
Via Barchart.com
Topics ETFs
News headline image
Kymera (KYMR) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Merck's Two-Drug HIV Regimen Challenges Industry Standards Following Positive Phase 3 Results
Via MarketMinute
Topics Intellectual Property
News headline image
Arcus (RCUS) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Gilead’s Twice-Yearly HIV Breakthrough: A Paradigm Shift in Global Prevention and Market Dominance
Via MarketMinute
Topics Intellectual Property
News headline image
Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics
Via MarketMinute
Topics Intellectual Property
News headline image
Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Snaps Up Arcellx For $115 Per Share — A $7.8 Billion Bet On Cancer Therapy ↗
Via Benzinga
News headline image
Is Amgen Stock Outperforming the Dow?
Via Barchart.com
Topics Stocks
News headline image
2 Nasdaq 100 Stocks Worth Your Attention and 1 We Question
Via StockStory
News headline image
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Bets Big On Anito-Cel With $7.8 Billion Arcellx Deal ↗
Via Investor's Business Daily
News headline image
Gilead Buys Arcellx To Fast-Track Next-Gen Myeloma Drug ↗
Via Benzinga
News headline image
Why Did ACLX Stock Surge 80% In Pre-Market Today? ↗
Via Stocktwits
News headline image
Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel
From Arcellx, Inc.
Via Business Wire
News headline image
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million ↗
Via The Motley Fool
News headline image
Where Gilead Sciences Stands With Analysts ↗
Via Benzinga
News headline image
Peering Into Gilead Sciences Inc's Recent Short Interest ↗
Via Benzinga

Frequently Asked Questions

Is Gilead Sciences publicly traded?
Yes, Gilead Sciences is publicly traded.
What exchange does Gilead Sciences trade on?
Gilead Sciences trades on the Nasdaq Stock Market
What is the ticker symbol for Gilead Sciences?
The ticker symbol for Gilead Sciences is GILD on the Nasdaq Stock Market
What is the current price of Gilead Sciences?
The current price of Gilead Sciences is 150.03
When was Gilead Sciences last traded?
The last trade of Gilead Sciences was at 03/02/26 04:00 PM ET
What is the market capitalization of Gilead Sciences?
The market capitalization of Gilead Sciences is 188.11B
How many shares of Gilead Sciences are outstanding?
Gilead Sciences has 188B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

© Copyright 2015, Daily Courier, Kelowna, BC. Powered by BLOX Content Management System from TownNews.com.